Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.

Autor: Seligson ND; Department of Pharmacotherapy and Translational Research, The University of Florida, Jacksonville, FL, USA.; Department of Pharmacogenomics and Translational Research, Nemours Children's Specialty Care, Jacksonville, FL, USA.; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Nemours Children's Specialty Care, Jacksonville, FL, USA., Maradiaga RD; The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Stets CM; The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Katzenstein HM; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Nemours Children's Specialty Care, Jacksonville, FL, USA., Millis SZ; Foundation Medicine Inc, Cambridge, USA., Rogers A; Department of Radiology, The Ohio State University, Columbus, OH, USA., Hays JL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, USA., Chen JL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. James.Chen@osumc.edu.; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA. James.Chen@osumc.edu.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2021 May 21; Vol. 5 (1), pp. 43. Date of Electronic Publication: 2021 May 21.